Olumiant® ▼ (baricitinib)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information: Olumiant Summary of Product Characteristics (SmPC)

Olumiant® ▼ (baricitinib): Dosing in elderly patients

Age ≥ 65 years or ≥ 75 years has no effect on baricitinib exposure (Cmax and AUC). (Olumiant Summary of Product Characteristics)

Summary

In a post hoc analysis of 2 pooled phase 3 clinical trials, age did not affect the efficacy of baricitinib (BARI); however, more adverse events (AEs) were reported in the elderly.1

Clinical experience in patients ≥ 75 years is very limited and in these patients a starting dose of 2 mg is appropriate.2

References

1. Fleischmann R, Alam J, Arora V, et al. Safety and efficacy of baricitinib in elderly patients with rheumatoid arthritis. RMD Open. 2017;3(2):1-5. http://dx.doi.org/10.1136/rmdopen-2017-000546

2. Olumiant [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

Glossary

AUC:  Area Under the Curve

Cmax: maximum Concentration

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Date of Last Review: October 13, 2017

Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 8am - 4pm, excluding Bank Holidays

Or you can

Ask us a question Chat with Us If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a question